Federated Hermes Inc. Cuts Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Federated Hermes Inc. lowered its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 9.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 818,027 shares of the biopharmaceutical company’s stock after selling 83,482 shares during the quarter. Federated Hermes Inc.’s holdings in Vanda Pharmaceuticals were worth $3,452,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of VNDA. Mackenzie Financial Corp purchased a new position in Vanda Pharmaceuticals during the 4th quarter worth $46,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Vanda Pharmaceuticals by 352.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,658 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 5,186 shares in the last quarter. Raymond James & Associates purchased a new position in Vanda Pharmaceuticals during the fourth quarter worth about $42,000. Profit Investment Management LLC grew its position in Vanda Pharmaceuticals by 19.0% in the 4th quarter. Profit Investment Management LLC now owns 389,274 shares of the biopharmaceutical company’s stock worth $1,643,000 after purchasing an additional 62,277 shares in the last quarter. Finally, Public Employees Retirement System of Ohio increased its stake in Vanda Pharmaceuticals by 13.7% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 75,648 shares of the biopharmaceutical company’s stock valued at $327,000 after buying an additional 9,100 shares during the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Price Performance

NASDAQ VNDA opened at $4.62 on Friday. The business’s fifty day moving average is $4.27 and its 200-day moving average is $4.08. The stock has a market capitalization of $265.83 million, a price-to-earnings ratio of 92.42 and a beta of 0.76. Vanda Pharmaceuticals Inc. has a one year low of $3.30 and a one year high of $7.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05. The business had revenue of $45.27 million during the quarter, compared to the consensus estimate of $37.00 million. Vanda Pharmaceuticals had a net margin of 1.30% and a return on equity of 0.46%. Research analysts expect that Vanda Pharmaceuticals Inc. will post -0.06 EPS for the current fiscal year.

Analyst Ratings Changes

VNDA has been the topic of several recent analyst reports. StockNews.com cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, April 22nd. TheStreet lowered Vanda Pharmaceuticals from a “c-” rating to a “d” rating in a report on Thursday, February 8th.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.